Plasma and serum concentrations of VEGF-A121, but not of VEGF-A165, increase post-bevacizumab administration.

Plasma and serum concentrations of VEGF-A121, but not of VEGF-A165, increase post-bevacizumab administration.

<h4>Background</h4>VEGF-A concentrations were measured in the blood of bevacizumab-treated cancer patients in previous studies, but a consensus has not formed that would develop VEGF-A into a clinical biomarker. Recently, methods to strictly distinguish between the VEGF-A isoforms have b...

Full description

Saved in:
Bibliographic Details
Main Authors: Masashi Okawa, Munekazu Yamakuchi, Aryal Bibek, Kazunori Takenouchi, Drew N Maywar, Shingo Yamada, Keiichi Inoue, Kazuhiko Higurashi, Junichi Nakazawa, Masahiro Kawahira, Tomoko Kodama, Kiyonori Tanoue, Yoko Oyama, Sadayuki Higashi, Chieko Fujisaki, Hirohito Hashinokuchi, Akito Tabaru, Hideaki Kanda, Shuji Tachioka, Yutaka Imoto, Teruto Hashiguchi, Yoshiharu Soga
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2024-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0316035
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1371/journal.pone.0316035

Similar Items